revefenacin: Clinical Trials

20 trials of revefenacin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 1 not yet recruiting, 1 recruiting. 6 Phase 3, 5 Phase 1, 5 Phase 2, 4 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 36Completed 6
Phase 15Completed 5
Phase 25Completed 5
Phase 44Completed 2, Not yet recruiting 1, Recruiting 1

Follow revefenacin: new trials by email Literature Review of revefenacin trials Research Report on revefenacin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)
Revefenacin, formoterol fumarate, Placebo (Sterile Normal Saline) - COPD Exacerbation
Phase 4Not yet recruitingUniversity of Tennessee Graduate School of Medicine2802026-11-122026-10-19
Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ) - COPD (Chronic Obstructive Pulmonary Disease)
Phase 4RecruitingUniversity of Tennessee Graduate School of Medicine722023-12-052026-10-19
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
Revefenacin, Tiotropium, Revefenacin Placebo - Chronic Obstructive Pulmonary Disease
Phase 4CompletedTheravance Biopharma4042022-01-072024-12-20
Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)
Revefenacin 175 mcg in 3 ML Inhalation Solution, Placebo inhalation solution QD - COPD
Phase 3CompletedMylan Pharma UK Ltd.2582021-11-102024-11-01
Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution
Revefenacin Inhalation Solution - Healthy Volunteers Bioavailability Study
Phase 1CompletedMylan Pharma UK Ltd.242021-09-232022-04-04
Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic) - COPD Exacerbation
Phase 4CompletedUniversity of Tennessee Graduate School of Medicine602020-12-092026-08-03
Revefenacin in Acute Respiratory Insufficiency in COPD
Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide - COPD, Acute Respiratory Failure
Phase 2CompletedUniversity of California, Los Angeles212020-11-012026-10-14
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
Revefenacin, Placebo, Formoterol - Chronic Obstructive Pulmonary Disease (COPD)
Phase 3CompletedMylan Inc.1222018-05-312022-02-24
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
Revefenacin, Spiriva Handihaler®, Placebo for Revefenacin - Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
Phase 3CompletedMylan Inc.2072017-03-272022-02-24
Thorough QT (TQT) Study of TD-4208 in Healthy Subjects
TD-4208 175 mcg, TD-4208 700 mcg, Placebo for TD-4208 - Cardiac Repolarization in Healthy Subjects
Phase 1CompletedMylan Inc.482016-05-012022-02-24
Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment
TD-4208 - Renal Impairment
Phase 1CompletedMylan Inc.162015-12-012022-02-24
Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment
TD-4208 - Hepatic Impairment
Phase 1CompletedMylan Inc.162015-11-012022-02-24
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
TD-4208, Placebo - Chronic Obstructive Pulmonary Disease (COPD)
Phase 3CompletedMylan Inc.6112015-09-012022-02-24
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
TD-4208, Placebo - Chronic Obstructive Pulmonary Disease (COPD)
Phase 3CompletedMylan Inc.6192015-09-012022-02-24
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
TD-4208, Tiotropium - Chronic Obstructive Pulmonary Disease (COPD)
Phase 3CompletedMylan Inc.10602015-09-012022-02-24
TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
TD-4208 - Chronic Obstructive Pulmonary Disease (COPD)
Phase 1CompletedMylan Inc.92015-06-012022-02-24
A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
TD-4208, Placebo - COPD
Phase 2CompletedMylan Inc.3552014-05-012022-02-24
A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
TD-4208, Placebo - Chronic Obstructive Pulmonary Disease, COPD
Phase 2CompletedMylan Inc.642014-04-012022-02-24
7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
TD-4208, Placebo - COPD
Phase 2CompletedMylan Inc.622012-12-012022-02-24
Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Placebo, TD-4208 700 μg, TD-4208 350 μg - Chronic Obstructive Pulmonary Disease, COPD
Phase 2CompletedMylan Inc.322011-05-012022-02-24

Conditions studied

Pulmonary Disease, Chronic Obstructive (14)  ·  Bronchitis, Chronic (1)  ·  Emphysema (1)  ·  Hepatitis (1)  ·  Liver Cirrhosis (1)  ·  Renal Insufficiency (1)

Sponsors

Mylan Inc. (13)  ·  University of Tennessee Graduate School of Medicine (3)  ·  Mylan Pharma UK Ltd. (2)  ·  Theravance Biopharma (1)  ·  University of California, Los Angeles (1)

Countries

United States (16)  ·  China (2)  ·  New Zealand (2)

Top investigators

Andrew Shaw, PhD (1)  ·  Dik WH Ng, PhD (1)  ·  Donald Tashkin, MD (1)  ·  Igor Z Barjaktarevic, MD, PhD (1)

Results publications

PMID 33124005, PMID 31632000, PMID 32343967, PMID 32393215, PMID 36681255, PMID 38560416, PMID 28987804, PMID 29096627, PMID 31150963, PMID 31647854, PMID 31666076, PMID 39429809, PMID 42548489